Valdoxan’s onset of efficacy has been reported and measured on the Clinical Global Impression-Improvement [CGI-I] scale and Visual Analog Scales [VAS]as early as the first week of treatment. From the first week of treatment, Valdoxan demonstrated to provide significant efficacy in terms of CGI score improvement, as well as VAS score improvement.

Significant improvement in CGI score at week 1 with Valdoxan

In a 6-week randomized, double-blind study conducted in 332 patients with major depressive disorder, Valdoxan was demonstrated to provide early onset of antidepressant efficacy as reported by a significant clinical improvement from the first week of treatment on the CGI-I scale (Δ=0.39 in favour of Valdoxan 25-50 mg/day compared with venlafaxine IR 75-150 mg/day, P=0.0001).

Lemoine P. et al. J Clin Psychiatry. 2007;68:1723-1732.

Significant improvement in VAS score at week 1 with Valdoxan

At 1 week just after initiation in a randomized, double-blind study conducted in 332 patients with major depressive disorder, Valdoxan demonstrated on VAS scales a significant improvement versus venlafaxine IR 75-150 mg/day in the sensation of “feeling good” (P<0.001), as well as in “daytime vigilance” and “quality of sleep,” two core symptoms of depression, as early as the first week of treatment.

Lemoine P. et al. J Clin Psychiatry. 2007;68:1723-1732.

Efficacy in the short term